Cargando…

Pharmaceutical Pricing Policy in Greece: Toward a Different Path

BACKGROUND: Affordable, accessible, and innovation-promoting pharmaceutical care is essential to the operation of a sustainable health system. External reference pricing (ERP), a common pharmaceutical policy in Europe, suffers today from indigenous weaknesses that may cause market distortions and ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Souliotis, Kyriakos, Papageorgiou, Manto, Politi, Anastasia, Athanasiadis, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005395/
https://www.ncbi.nlm.nih.gov/pubmed/27630983
http://dx.doi.org/10.3389/fpubh.2016.00185
_version_ 1782450918128615424
author Souliotis, Kyriakos
Papageorgiou, Manto
Politi, Anastasia
Athanasiadis, Athanasios
author_facet Souliotis, Kyriakos
Papageorgiou, Manto
Politi, Anastasia
Athanasiadis, Athanasios
author_sort Souliotis, Kyriakos
collection PubMed
description BACKGROUND: Affordable, accessible, and innovation-promoting pharmaceutical care is essential to the operation of a sustainable health system. External reference pricing (ERP), a common pharmaceutical policy in Europe, suffers today from indigenous weaknesses that may cause market distortions and barriers to care, burdening mostly the weak economies, and hence, raising ethical and political worrying. OBJECTIVES AND METHODS: A non-randomized experiment was conducted, in order to examine the influence of flexible and adaptable to health systems’ affordability ERP structures. Outcomes were assessed by measuring deviations from Greek prices’ level ex ante, as well as effects on pharmaceutical markets affiliated to the European ERP system. RESULTS AND CONCLUSION: Pharmaceutical pricing models that fit prices to income and affordability are better in all aspects, as they produce fairer results, while resulting in low external costs for the European ERP network as a whole. Small sets of reference countries are preferred to large baskets, as they produce similar results, while presenting better qualities by increasing the flexibility of the reimbursement system and the transparency of the market.
format Online
Article
Text
id pubmed-5005395
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-50053952016-09-14 Pharmaceutical Pricing Policy in Greece: Toward a Different Path Souliotis, Kyriakos Papageorgiou, Manto Politi, Anastasia Athanasiadis, Athanasios Front Public Health Public Health BACKGROUND: Affordable, accessible, and innovation-promoting pharmaceutical care is essential to the operation of a sustainable health system. External reference pricing (ERP), a common pharmaceutical policy in Europe, suffers today from indigenous weaknesses that may cause market distortions and barriers to care, burdening mostly the weak economies, and hence, raising ethical and political worrying. OBJECTIVES AND METHODS: A non-randomized experiment was conducted, in order to examine the influence of flexible and adaptable to health systems’ affordability ERP structures. Outcomes were assessed by measuring deviations from Greek prices’ level ex ante, as well as effects on pharmaceutical markets affiliated to the European ERP system. RESULTS AND CONCLUSION: Pharmaceutical pricing models that fit prices to income and affordability are better in all aspects, as they produce fairer results, while resulting in low external costs for the European ERP network as a whole. Small sets of reference countries are preferred to large baskets, as they produce similar results, while presenting better qualities by increasing the flexibility of the reimbursement system and the transparency of the market. Frontiers Media S.A. 2016-08-31 /pmc/articles/PMC5005395/ /pubmed/27630983 http://dx.doi.org/10.3389/fpubh.2016.00185 Text en Copyright © 2016 Souliotis, Papageorgiou, Politi and Athanasiadis. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Souliotis, Kyriakos
Papageorgiou, Manto
Politi, Anastasia
Athanasiadis, Athanasios
Pharmaceutical Pricing Policy in Greece: Toward a Different Path
title Pharmaceutical Pricing Policy in Greece: Toward a Different Path
title_full Pharmaceutical Pricing Policy in Greece: Toward a Different Path
title_fullStr Pharmaceutical Pricing Policy in Greece: Toward a Different Path
title_full_unstemmed Pharmaceutical Pricing Policy in Greece: Toward a Different Path
title_short Pharmaceutical Pricing Policy in Greece: Toward a Different Path
title_sort pharmaceutical pricing policy in greece: toward a different path
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005395/
https://www.ncbi.nlm.nih.gov/pubmed/27630983
http://dx.doi.org/10.3389/fpubh.2016.00185
work_keys_str_mv AT souliotiskyriakos pharmaceuticalpricingpolicyingreecetowardadifferentpath
AT papageorgioumanto pharmaceuticalpricingpolicyingreecetowardadifferentpath
AT politianastasia pharmaceuticalpricingpolicyingreecetowardadifferentpath
AT athanasiadisathanasios pharmaceuticalpricingpolicyingreecetowardadifferentpath